BIOINFORMATICS TOOLS FOR PHARMACEUTICAL DRUG PRODUCT DEVELOPMENT (HB 2023). Cet article n’est pas disponible.BIOINFORMATICS TOOLS FOR PHARMACEUTICAL DRUG PRODUCT DEVELOPMENT (HB 2023)

A timely book that details bioinformatics tools, artificial intelligence, machine learning, computational methods, protein interactions, peptide-based drug design, and omics technologies, for drug development in the pharmaceutical and medical sciences industries.

The book contains 17 chapters categorized into 3 sections. The first section presents the latest information on bioinformatics tools, artificial intelligence, machine learning, computational methods, protein interactions, peptide-based drug design, and omics technologies. The following 2 sections include bioinformatics tools for the pharmaceutical sector and the healthcare sector. Bioinformatics brings a new era in research to accelerate drug target and vaccine design development, improving validation approaches as well as facilitating and identifying side effects and predicting drug resistance. As such, this will aid in more successful drug candidates from discovery to clinical trials to the market, and most importantly make it a more cost-effective process overall.

Readers will find in this book:

• Applications of bioinformatics tools for pharmaceutical drug product development like process development, pre-clinical development, clinical development, commercialization of the product, etc.;
• The ever-expanding application of this novel technology and discusses some of the unique challenges associated with such an approach;
• The broad and deep background, as well as updates, on recent advances in both medicine and AI/ML that enable the application of these cutting-edge bioinformatics tools.

Audience

The book will be used by researchers and scientists in academia and industry including drug developers, computational biochemists, bioinformaticians, immunologists, pharmaceutical and medical sciences, as well as those in artificial intelligence and machine learning.

Vivek Chavda, M. Pharm, is an assistant professor in the Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Ahmedabad, India. He has more than 40 research articles in international journals.

Krishnan Anand, PhD, is a research scientist in the Department of Chemical Pathology, University of the Free State, Bloemfontein, South Africa. He has more than 40 research articles in international journals and his research interests are in organic chemistry, medicinal chemistry, chemical pathology, bioinformatics, and nanotechnology.

Vasso Apostolopoulos, PhD, is at the Institute for Health and Sport, Immunology and Translational Research Group, Victoria University, Melbourne, Australia. She received her PhD in immunology in 1995 from the University of Melbourne, and the Advanced Certificate in Protein Crystallography from Birkbeck College, University of London. Professor Vasso Apostolopoulos is a world-renowned researcher who has been recognized with over 100 awards for the outstanding results of her research and she was named one of the most successful Greeks abroad by the prestigious Times magazine. Vasso was the first in the world to develop the concept of immunotherapy for cancer in the early 1990s, which today is used by hundreds of labs around the world. Immunotherapy aims to boost specific immune cells and program them to kill cancer cells; it was used by Vasso to develop the world's first breast cancer vaccine with phase I, II, and III clinical trials completed. Of note, one of the studies now has long-term follow-up data showing that 20 years later those injected with the vaccine remain cancer free.